127 related articles for article (PubMed ID: 18331373)
1. Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein.
Bonhomme-Faivre L; Benyamina A; Reynaud M; Farinotti R; Abbara C
Addict Biol; 2008 Sep; 13(3-4):295-300. PubMed ID: 18331373
[TBL] [Abstract][Full Text] [Related]
2. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
[TBL] [Abstract][Full Text] [Related]
3. Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
Chu C; Abbara C; Noël-Hudson MS; Thomas-Bourgneuf L; Gonin P; Farinotti R; Bonhomme-Faivre L
Biochem Pharmacol; 2009 May; 77(10):1629-34. PubMed ID: 19426700
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
Kalvass JC; Olson ER; Pollack GM
Drug Metab Dispos; 2007 Mar; 35(3):455-9. PubMed ID: 17178769
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
[TBL] [Abstract][Full Text] [Related]
6. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice.
Castagne V; Bonhomme-Faivre L; Urien S; Ben Reguiga M; Soursac M; Gimenez F; Farinotti R
Drug Metab Dispos; 2004 Feb; 32(2):168-71. PubMed ID: 14744937
[TBL] [Abstract][Full Text] [Related]
7. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
Press RR; Buckle T; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2006 Jun; 57(6):819-25. PubMed ID: 16163538
[TBL] [Abstract][Full Text] [Related]
8. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
Gnoth MJ; Sandmann S; Engel K; Radtke M
Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
[TBL] [Abstract][Full Text] [Related]
9. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier.
Milane A; Fernandez C; Vautier S; Bensimon G; Meininger V; Farinotti R
J Neurochem; 2007 Oct; 103(1):164-73. PubMed ID: 17635670
[TBL] [Abstract][Full Text] [Related]
10. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells.
Washington CB; Wiltshire HR; Man M; Moy T; Harris SR; Worth E; Weigl P; Liang Z; Hall D; Marriott L; Blaschke TF
Drug Metab Dispos; 2000 Sep; 28(9):1058-62. PubMed ID: 10950849
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Tahara H; Kusuhara H; Fuse E; Sugiyama Y
Drug Metab Dispos; 2005 Jul; 33(7):963-8. PubMed ID: 15821041
[TBL] [Abstract][Full Text] [Related]
12. Effect of interferon-gamma on the pharmacokinetics of digoxin, a P-glycoprotein substrate, intravenously injected into the mouse.
Kawaguchi H; Matsui Y; Watanabe Y; Takakura Y
J Pharmacol Exp Ther; 2004 Jan; 308(1):91-6. PubMed ID: 14569074
[TBL] [Abstract][Full Text] [Related]
13. Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice.
Chen C; Pollack GM
J Pharmacol Exp Ther; 1998 Nov; 287(2):545-52. PubMed ID: 9808679
[TBL] [Abstract][Full Text] [Related]
14. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein.
Kwei GY; Alvaro RF; Chen Q; Jenkins HJ; Hop CE; Keohane CA; Ly VT; Strauss JR; Wang RW; Wang Z; Pippert TR; Umbenhauer DR
Drug Metab Dispos; 1999 May; 27(5):581-7. PubMed ID: 10220486
[TBL] [Abstract][Full Text] [Related]
15. Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain.
Zhao R; Pollack GM
Biochem Pharmacol; 2009 Oct; 78(8):1052-9. PubMed ID: 19523457
[TBL] [Abstract][Full Text] [Related]
16. Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.
Bundgaard C; Jensen CJ; Garmer M
Drug Metab Dispos; 2012 Mar; 40(3):461-6. PubMed ID: 22112383
[TBL] [Abstract][Full Text] [Related]
17. Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs.
Mealey KL; Waiting D; Raunig DL; Schmidt KR; Nelson FR
J Vet Pharmacol Ther; 2010 Oct; 33(5):453-60. PubMed ID: 20840389
[TBL] [Abstract][Full Text] [Related]
18. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.
Brenneisen R; Egli A; Elsohly MA; Henn V; Spiess Y
Int J Clin Pharmacol Ther; 1996 Oct; 34(10):446-52. PubMed ID: 8897084
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin.
Ito K; Nguyen HT; Kato Y; Wakayama T; Kubo Y; Iseki S; Tsuji A
J Control Release; 2008 Nov; 131(3):198-204. PubMed ID: 18725258
[TBL] [Abstract][Full Text] [Related]
20. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.
Smit JW; Huisman MT; van Tellingen O; Wiltshire HR; Schinkel AH
J Clin Invest; 1999 Nov; 104(10):1441-7. PubMed ID: 10562306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
